Summary

Insulin degludec is superior to sitagliptin in improving glycemic control in patients with type 2 diabetes mellitus uncontrolled by oral antidiabetic drugs (OADs). This article discusses the results of the comparison of NN1250 with Sitagliptin in Subjects with Type 2 Diabetes Never Treated with Insulin [BEGIN®: EARLY; NCT01046110] trial that compared basal insulin with a dipeptidyl peptidase-4 inhibitor as an add-on to OADs.